Other languages Cidara Therapeutics, Inc.

Equities

CDTX

US1717571079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.722 ^USD	-0.03%		-16.44%	-9.07%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults	Jan. 29
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China	Dec. 06
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	Dec. 05
Cidara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults	23-10-13
Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023	23-10-11
Cidara Therapeutics, Inc. Announces Janssen?S Election to Proceed Under Its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza	23-09-06
Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development	23-08-16
Cidara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Cidara Therapeutics Says Partner Melinta Therapeutics Launched Candidemia Treatment Rezzayo in US	23-08-01
Cidara Therapeutics Provides Update on REZZAYO? (Rezafungin for Injection)	23-07-31
Cidara Therapeutics Says US FDA Grants Fast Track Designation to Influenza Drug Candidate	23-06-22
Cidara Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B	23-06-22
Cidara Therapeutics, Inc. to Present Highlights from Its Ongoing Preclinical Studies of CD421 as Well as the Development of Its Novel Drug-Fc Conjugates from Cidara’s Cloudbreak® Platform	23-06-13
Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Cidara Therapeutics Gets $20 Million Milestone Payment After FDA Approves Rezzayo to Treat Candidemia	23-04-24
Cidara Therapeutics, Inc. Therapeutics Receives $20 Million Milestone Payment Following U.S. Food and Drug Administration Approval of REZZAYO™	23-04-24
HVIVO touts positive test results from seasonal flu drug, CD388	23-04-03
HVIVO plc Announces Positive Interim Results from an Ongoing Human Challenge Study Testing CD388	23-04-03
Sector Update: Health Care Stocks Mixed During Late Afternoon	23-03-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cidara Therapeutics, Inc.

Equities

CDTX

US1717571079

Other languages

Filters